There’s a quotidian calculation to outsourcing at Allena Pharmaceuticals that's well worth studying.
“As a small biotech, we could get kicked to the curb because somebody else has more dollars, and can occupy longer those assets at a CMO that we need. Because of this, we’ve evolved a concept of portability for our manufacturing process that may be anathema to a lot of companies …"
Opportunities related to the world’s third largest pharma industry tend to get drowned out by U.S. domestic events, and news from Europe, China, and even India. But if you haven’t been, it’s time to start paying attention to Japan again. There are opportunities for partnering, providing services to Japan Pharma, and for market penetration by foreign biopharma companies.
We’ve heard stories where service providers bring ideas for innovations to biopharma clients, but get rebuked because of the immediate focus on the bottom line for services. Perhaps sponsors should make a new comparison: Where is innovative, biopharma-applicable new-tech, perhaps already focused on elements of a drug owner’s pipeline, actually cheaper to come by?
Outsourced Pharma readers must be scratching your heads over the mass-media reported news splash that Intermountain Healthcare is leading four U.S.-based “health care systems” in a consortium to form a generic drug company. In other words, hospitals are getting into APIs. And this, we are told, will save the world from shortages, while reducing pricing for generic drugs. Let’s just say some questions remain, such as: “How’s that all going to work?”
We could never get away with “fake news” here. You’d run us out of town in a New York minute. But here’s some thoughts and historical perspective on this theme swirling around us today.
If you’re interested in new tech and innovation – including outside of the biopharma space – and enjoy warm weather and coastlines, you won’t help but envy Ravi Kiron. Merck KGaA has given him the job of all jobs. Kiron has became the head of biopharma external innovation at Merck’s EMD Serono, Inc., and tasked with establishing its Silicon Valley Innovation Hub. Try not to be too jealous of Kiron as you’re reading. More jobs like his may be on the way.
When queried about the areas of most importance to them, their companies, and the biopharma outsourcing industry over the next 12 months, experienced professionals from around the world came back with this: cells, cells, and more cells.
It’s time for our 2018 industry outlook. But don’t worry if you’ve already had your share of forecasts slipped into your stockings. I promise ours brings something different to the prognostication party. And it should help readers to consider carefully what you need to focus on to make it another successful year.
How does the modern-day CMC leader at drug sponsors get the job done? Michael Markey, newly appointed CMC Director, Pharmaceutical Sciences, Radius Health, Inc., says applying past experiences from working at CDMOs helps. However, there’s a lesson he’s learned since joining Radius, and it has to do with branding and the marketing of contract services.
New CMC leader — and former colleague — Mike Markey says, “What’s most important to remember about a virtual company is all of our functions work at a desk. None of us actually have hands on; we rely on our CMO partners to get the work done. For me, the external project managers become an integral part of my day-to-day work.”